Molecular and Translational Oncology Research

分子和转化肿瘤学研究

• 批准号: 9280411
• 负责人: JOHN BLENIS
• 金额: $ 27.23万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-01 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9280411
• 关键词: Molecular; Research; oncology

ABSTRACT The past decade, an explosion of research and technological achievements in molecular oncology and genomics have offered an unprecedented opportunity to transform patient care. This shift in the traditional cancer research paradigm, demands for more sophisticated skills to be acquired by cancer scientists. We are requesting support via a new T32 training grant for the research training of four postdoctoral fellows in Molecular and Translational Oncology Research (MTOR) at Weill Cornell Medicine (WCM). WCM will provide funding for an additional fifth training slot. The objective of this program is to recruit the best possible candidates with a solid foundation in basic science and train them in molecular and translational oncology so that they can apply their knowledge to address important clinically unmet needs in the prevention, diagnosis, and treatment of cancer patients. MTOR trainees will receive program support for two years during which they will follow a structured and rigorous postdoctoral training path. The MTOR program is a joint effort of 17 outstanding WCM preceptors and co-mentors, and a dense network of clinical collaborators, who are international leaders in their respective fields. Trainees will further profit from the leveraging of institutional resources such as the Sandra and Edward Meyer Cancer Center and Weill Cornell's Clinical and Translational Science Center (CTSC). MTOR's highly personalized training plan will include 1) individual development plans and customized workplans; 2) rigorous translationally focused research training; 3) hands-on experience in cutting-edge methodologies; and 4) a comprehensive curriculum of innovative core and ancillary skill acquisition workshops, including writing, leadership, communication, and entrepreneurial perspectives. We anticipate a pool of at least 300 candidates. We have assembled an outstanding roster of external and internal advisory committee members with the mandate to evaluate the program and provide specific recommendations to improve its efficiency. MTOR has a strong diversity focus and through its rigorous, structured and highly personalized curriculum, seeks to train the future leaders in translational cancer research in the USA.

摘要 在过去的十年里，分子肿瘤学和基因组学方面的研究和技术成果激增 为改变病人护理提供了前所未有的机会。这种传统癌症研究范式的转变， 癌症科学家需要掌握更复杂的技能。我们正在通过新的T32请求支持 四名分子和转译肿瘤学博士后研究员研究培训补助金 (MTOR)，威尔·康奈尔医学院(WCM)。WCM将为额外的第五个培训时段提供资金。这个 该计划的目标是招募在基础科学和培训方面有坚实基础的最好的应聘者 分子和翻译肿瘤学，以便他们可以应用他们的知识来处理重要的临床 在癌症患者的预防、诊断和治疗方面未得到满足的需求。MTOR实习生将获得 支持为期两年，在此期间，他们将遵循系统和严格的博士后培训道路。MTOR 该计划由17名杰出的WCM导师和共同导师共同努力，并建立了一个密集的临床网络 合作者，他们是各自领域的国际领导者。学员将进一步从杠杆中获利 机构资源，如桑德拉和爱德华·迈耶癌症中心和威尔·康奈尔的临床和 翻译科学中心(CTSC)。MTOR的高度个性化培训计划将包括1)个人 发展计划和定制工作计划；2)严格的翻译研究培训；3)实践 具有尖端方法的经验；以及4)具有创新核心和辅助技能的综合课程 收购研讨会，包括写作、领导力、沟通和创业观点。我们期待着 至少有300名候选人。我们已经组建了一批优秀的外部和内部咨询委员会 有权评估该计划并提供具体建议以提高其效率的成员。 MTOR具有强烈的多样性重点，并通过其严格、结构化和高度个性化的课程，寻求 在美国培养未来的转化型癌症研究领导者。